戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rusor overactivity and those with idiopathic detrusor overactivity.
2 gaining importance in the pathophysiology of detrusor overactivity.
3  neurogenic and probably also non-neurogenic detrusor overactivity.
4 ave transformed the management of neurogenic detrusor overactivity.
5  by targeting alternative pathways affecting detrusor overactivity.
6 act symptoms/overactive bladder syndrome/and detrusor overactivity.
7                      Approximately half have detrusor overactivity and a smaller number have impaired
8  established in the management of refractory detrusor overactivity and overactive bladder.
9 urrent therapeutic alternatives for managing detrusor overactivity and possible future developments a
10 wn to increase cystometric capacity, inhibit detrusor overactivity and resolve overactive bladder sym
11  treatment, both in patients with neurogenic detrusor overactivity and those with idiopathic detrusor
12 ive in reducing incontinence associated with detrusor overactivity, and repeated treatments appear sa
13 nary incontinence, overflow incontinence and detrusor overactivity are the major categories of urinar
14            Bladders of DKO animals exhibited detrusor overactivity at an early stage: increased frequ
15 with pressure-flow urodynamics demonstrating detrusor overactivity, in the setting of a clinically re
16                                              Detrusor overactivity is a relatively common yet embarra
17                                              Detrusor overactivity is a relatively common yet embarra
18  in our understanding of the pathogenesis of detrusor overactivity is slow but steady.
19                                              Detrusor overactivity is the occurrence of abnormal incr
20                                   Neurogenic detrusor overactivity (NDO) is a well known consequence
21                                   Neurogenic detrusor overactivity (NDO) is among the most challengin
22  multiple sclerosis often develop neurogenic detrusor overactivity (NDO), which currently lacks a uni
23 onventional treatments like drug therapy for detrusor overactivity or sling procedures for female str
24                                              Detrusor overactivity poses a major challenge to physici
25 tract dysfunction, especially for those with detrusor overactivity refractory to anticholinergics, is
26                              We propose that detrusor overactivity results from exaggerated symptomat
27 r hypersensitivity as well as non-neurogenic detrusor overactivity, there is up-regulation of unmyeli
28 ts acting on alternative pathways underlying detrusor overactivity with the intention of improving st

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。